CSL News Today: Meningococcal B Vaccine Sees Surging Demand After Outbreak

CSL Limited (CSL.AX), a leading biotechnology firm, is currently in the spotlight as demand for the meningococcal B vaccine surges following a recent outbreak in Australia. This development has drawn significant attention from investors and the public health sector. The increased demand not only highlights the importance of the vaccine but also points to potential growth in the vaccine market, especially for companies like CSL that are focused on immunization solutions.